New hope for elderly myeloma patients: drug combo trial launches
NCT ID NCT04751877
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether adding the drug isatuximab to a standard combination of lenalidomide and dexamethasone, with or without bortezomib, can improve outcomes for newly diagnosed multiple myeloma patients aged 65 to 79 who are not eligible for a stem cell transplant. The study will enroll 270 participants and measure how well the treatment reduces cancer cells to very low levels. The goal is to find a more effective and tolerable treatment option for this older population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Isatuximab, lenalidomide, bortezomib, and dexamethasone
What this could lead to
If successful, this could provide a more effective and tolerable treatment option for elderly multiple myeloma patients who cannot have a stem cell transplant.
What could go wrong
This is an early-phase study with a moderate number of participants. The combination may cause side effects, and it is not yet known if it will improve long-term outcomes compared to existing therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Poitiers
Poitiers, 86000, France